[短程水化 S-1 联合顺铂方案对门诊胃癌患者肾毒性的分析]
[Analysis of Renal Toxicity of S-1 plus CDDP Regimen with Short Hydration for Outpatients with Gastric Cancer].
作者信息
Hasegawa Tsuyoshi, Teraoka Hitoshi, Mori Takuya, Kinoshita Haruhito, Nakamoto Kentaro, Noda Eiji, Hirakawa Kosei, Ohira Masaichi
机构信息
Dept. of Surgery, Baba Memorial Hospital.
出版信息
Gan To Kagaku Ryoho. 2019 Dec;46(13):2407-2409.
BACKGROUND
Although the S-1 plus CDDP(SP)regimen is the standard treatment for advanced gastric cancer, hydration and admission have been recommended after cisplatin has been administered. In this study, short hydration(SH)method was used and SP was administered in outpatient settings. We evaluated renal toxicity of cisplatin in the SH-SP regimen at our hospital.
METHODS
Eleven of 16 patients(5 underwent only 1 course and so were excluded)received the SH-SP regimen between January 2012 and January 2018 to present and were included. Serum creatinine(Cr)and estimated glomerular filtration rate(eGFR)were used to assess renalfunction.
RESULTS
Median course was 5. Rate of 5-course accomplishment was 72.7%. Grade 1 Cr elevation was observed in only 3 patients and there was no severe renal disorder.
CONCLUSION
The SHSP regimen could be administered in outpatient settings and was considered safe as it did not cause renal toxicity.
背景
尽管S-1联合顺铂（SP）方案是晚期胃癌的标准治疗方案，但顺铂给药后建议进行水化和住院治疗。在本研究中，采用了短程水化（SH）方法，并在门诊环境中给予SP。我们评估了我院SH-SP方案中顺铂的肾毒性。
方法
2012年1月至2018年1月期间，16例患者中有11例（5例仅接受1个疗程，因此被排除）接受了SH-SP方案并纳入研究。血清肌酐（Cr）和估算肾小球滤过率（eGFR）用于评估肾功能。
结果
中位疗程为5个疗程。5个疗程完成率为72.7%。仅3例患者观察到1级Cr升高，未出现严重肾脏疾病。
结论
SHSP方案可在门诊环境中给药，且因其未引起肾毒性而被认为是安全的。
Zotero 插件